Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751077 | 0.87 | PDGFRB (0.40) | LMNATP53RAB9ANPC1PDGFRA | |
| SCHEMBL5747258 | 0.84 | FGFR1 (0.48) | LMNATP53NPC1PDGFRAMAPT | |
| SCHEMBL5751015 | 0.81 | FGFR1 (0.63) | PDGFRAPDGFRBFGFR1SRC | |
| SCHEMBL5748530 | 0.81 | ABL1 (0.53) | PDGFRAPDGFRBFGFR1SRC | |
| SCHEMBL5747448 | 0.81 | NPC1 (0.45) | RAB9ANPC1POLBMEN1KMT2A | |
| SCHEMBL5747463 | 0.81 | EPHX1 (0.46) | RAB9ANPC1POLBMAPTEPHX1 | |
| SCHEMBL5748571 | 0.80 | NPC1 (0.51) | LMNATP53RAB9ANPC1POLB | |
| SCHEMBL5866816 | 0.80 | PDGFRA (0.46) | LMNARAB9ANPC1PDGFRAMEN1 | |
| SCHEMBL5749184 | 0.77 | ALDH1A1 (0.51) | LMNARAB9ANPC1POLBPDGFRA | |
| SCHEMBL5748810 | 0.77 | NPC1 (0.50) | LMNARAB9ANPC1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372648-B1 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| US-7005434-B2 | Compounds and uses thereof | SB CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040048888-A1 | Novel compounds and uses thereof | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048888-A1 | Novel compounds and uses thereof | TEK, TIE1, KDR | LMNA 4279/4885TP53 1206/4885RAB9A 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.